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Recent advancements in consumer directed personal computing technology have led to
the generation of biomedically-relevant data streams with potential health applications.
This has catalyzed international interest in Patient Generated Health Data (PGHD), defined
as “health-related data e including health history, symptoms, biometric data, treatment
history, lifestyle choices, and other information-created, recorded, gathered, or inferred
by or from patients or their designees (i.e. care partners or those who assist them) to
help address a health concern.”(Shapiro et al., 2012) PGHD offers several opportunities to
improve the efficiency and output of clinical trials, particularly within oncology. These
range from using PGHD to understand mechanisms of action of therapeutic strategies, to
understanding and predicting treatment-related toxicity, to designing interventions to
improve adherence and clinical outcomes. To facilitate the optimal use of PGHD, method-
ological research around considerations related to feasibility, validation, measure selec-
tion, and modeling of PGHD streams is needed. With successful integration, PGHD can
catalyze the application of “big data” to cancer clinical research, creating both “n of 1”
and population-level observations, and generating new insights into the nature of health
and disease.
ª 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights
reserved.1. Background exponentially increased the breadth and depth of these dataIn recent years, technological advancements have enabled
consumers to interact with personal computing devices in
ways that produce large amounts of consumer-specific data.
As personal devices have grown more portable and powerful,
consumer-directed applications have proliferated and have.A. Wood).
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ochemical Societies. Publstreams. Accelerometers, geolocators, and physiological sen-
sors are now embedded in many personal computing devices.
Some devices continue to exist in standalone, multipurpose
computing form (e.g. smartphones, tablets, laptops, and desk-
tops), others in uni- or oligo-purpose “wearable” form (e.g.
wristbands, belt clips, skin patches), and still others that areished by Elsevier B.V. All rights reserved.
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ing amounts of active or passive consumer data entry, these
devices can provide day to day or even hour to hour informa-
tion about a person’s location, diet, movement, symptoms,
blood pressure, and heart rate.
Concurrently with these trends, the potential for “big data”
to reveal insights about the external environment has gripped
the public consciousness. Integrating multiple longitudinal
data sources to predictively model complex events has long
been a mainstay of activities as diverse as forecasting
weather, choosing stocks, or assembling professional sports
teams (Lewis, 2003). Entities in the for-profit, non-profit and
academic spheres have recognized the ability of newer
consumer-specific data streams to predict human behavior
and outcomes. For example, large retailers like Target use
data on consumer habits to identify and engage specific con-
sumers for marketing purposes (Duhigg, 2012). The increasing
amounts of data from personal devices promise to further









Heart Rate Beats per minute
Temperature Celsius/Fahrenheit
Environmental exposure Exposure-dependent




Exercise testing Self-administered 6 min
walk distance, others
Diet Calories, composition
Mood/stress levels Type, severity, frequency,
interference





Functional status Scale, instrument-dependent




Tobacco use Type, frequency
Alcohol use Type, frequency
Other
Social connectedness Activity (e.g. Facebook,
Twitter, others)
Financial data Medication and health
care expenditure co-pays2. Patient-generated health data
In clinical care, we recognize that our patients’ pathophysio-
logical trends and events outside of clinic are at least as rele-
vant to their health and disease as the brief snapshots of
pathophysiology that are provided at the time of clinic visits.
In the “big data” era, we can imagine using this information
to predictively model disease states and to inform health-
promoting interventions. Indeed, many of the newer
consumer-specific data streams produce information that is
biomedically relevant and which could inform research and
clinical care. In this regard, an international dialog has
emerged around health-related data that come specifically
from patients, outside of the more general consumer context.
These data are termed “Patient-generated health data” (PGHD)
and defined as “health-related datae including health history,
symptoms, biometric data, treatment history, lifestyle
choices, and other information-created, recorded, gathered,
or inferred by or from patients or their designees (i.e. care
partners or those who assist them) to help address a health
concern” (Shapiro et al., 2012).
As interest in PGHD has increased, we are now seeing a
convergence in consumer-directed personal technology and
health-related applications. Samsung andApple have recently
announced major digital health initiatives, with Apple’s fea-
tures integrated into their new operating system (iOS8) as
“HealthKit” and partnerships announcedwith theMayo Clinic
and the EPIC electronic health record, (Weise, 2014; Munro,
2014).
From a research standpoint, some of the device-generated
PGHD of greatest interest include vital signs, stress levels,
mood, physical activity, weight, diet, blood levels, medica-
tions, sleep patterns, tobacco and alcohol use, and environ-
mental exposures (California Institute for
Telecommunications and Information Technology, 2014). Un-
der the more expansive PGHD definition, patient-curated his-
tories, diaries, risk assessments, and reports of health and
functional status are also likely to contribute valuable infor-
mation within the research context. Additionally, other typesof data that are not specifically health-related could be co-
opted to generate health related insights, such as geolocation,
social, and financial information. Examples of PGHD with po-
tential relevance to clinical research are provided in Table 1. In
general, key features of PGHD are that: patients, not providers,
capture and record these data; PGHD is obtainable outside of
clinical encounters; PGHD is longitudinal, with the potential
for repeated measures over time; and PGHD can be collected
at high frequency intervals, enabling nearly continuous data
streams over extended periods of observation, depending on
the metric of interest.3. Improving clinical trials efficiency
As a separate issue, it is increasingly clear that there is amajor
need to improve the design and conduct of clinical trials in
biomedical research. In the current era, clinical trials are
expensive, inefficient, and time-consuming. While much has
beenwritten on these topics (Institute ofMedicine 2010), these
issues have had tangible consequences, including increasing
political pressure on large clinical trial cooperative groups,
and internalmandates among drug and devicemanufacturers
Example: Patient-reported symptoms (a form of Patient-
Reported Outcomes, or PROs) can be reported electroni-
cally or by phone, inside or outside of clinic. Multiple
prior studies have demonstrated that patient-reported
symptoms are more reliable and informative than clini-
cian report (Basch, 2014). Further, patient-reported
symptoms can be obtained outside of clinic and there-
fore more frequently than clinician report (Judson
et al., 2013). Other forms of PGHD, such as home heart
rate or blood pressure monitoring, may soon comple-
ment patient-reported symptoms to provide a more
complete picture of day to day physiology. In oncology,
several targeted therapeutics have on-target effects
associated with disease response, such as hypertension
with VEGF/VEGFR inhibitors, or rash with EGF/EGFR in-
hibitors (Liu and Kurzrock, 2014). A more complete data
stream of patient-reported symptom and vital sign data
for participants on clinical trials may allow for a clearer
elucidation of on-target physiological effects of thera-
peutic interventions.
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importantly, in many of the most significant areas of human
suffering and disease such as oncology, the underlying scien-
tific understanding of disease states is moving faster than the
development and execution of clinical trials to address man-
agement considerations. This mismatch of science and prac-
tice leads to trial results that become quickly outdated, and
lost opportunities to improve patient outcomes.
Against this background, PGHD may provide opportunities
to address some of the current shortcomings of cancer clinical
trials. In the observational context, PGHD can generate infor-
mation that may inform hypotheses and design consider-
ations related to future clinical trials. Within clinical trials,
PGHD may increase the value of each patient contribution
on a clinical trial by improving the characterization of previ-
ously unmeasured confounders, thus maximizing the infor-
mation gained from each trial and decreasing required
sample sizes for future studies. PGHD offers the potential to
increase the number of clinical observations and data points
per patient, leading to new scientific insights about the posi-
tive and negative effects of cancer treatments upon patient
outcomes.
In the remainder of this review, we will discuss potential
considerations related to the integration of PGHD into future
clinical trials. We will illustrate how PGHD can contribute to
findings that are generated by trials. We will also offer an
agenda for methodological research that we believe is critical
to informing future PGHD integration into studies, addressing
some of the current barriers and limitations to the use of
PGHD in clinical trials. Last, we will conclude with a vision
for what fully integrated PGHD may mean within the clinical
research environment of the future.4. Integration of PGHD into clinical trials
There are multiple potential ways in which PGHD can inform
and improve the design, conduct, and output of clinical trials.
We summarize a few of these ways here:Example: A Comprehensive Geriatric Assessment (CGA) is
a multi-domain instrument of PGHD, components of
which can be self-administered by patients inside or
outside of clinic. Common domains include functional
status, nutritional status, psychological health and social
support. The CGA can predict toxicities ofmedical or sur-
gical anti-cancer therapies, and distinguishes vulnera-
bility even among individuals who have been assessed
by clinicians to have “acceptable” performance status
(Kim and Hurria, 2013). CGAs can also unmask deficits
in individuals who are actively undergoing cancer treat-
ment. Further, although physical performance items in
CGAs such as gait speed are commonly physician-
performed, PGHD offers the ability to obtain physical
performance-based measurements outside of the clinic
setting, such as daily physical activity and falls. CGAs
are already being used to guide clinical trial participation
and treatment recommendations for older adults with4.1. Understanding mechanisms of action of therapeutic
interventions
Monitoring of participants on clinical trials varies widely by
context and by type of trial. Though intensive monitoring
through frequent clinic visits and biological correlates are
more common in earlier phase studies, the principle of
associating treatment with biological effect retains rele-
vance in all clinical trial settings. Insights gained from
earlier phase studies may benefit from validation in
advanced phase trials; further, inclusion of participants
with varied underlying host phenotypes may require re-
affirmation of biological treatment effects in order to gener-
alize study results to a larger population. In this context,
PGHD may provide important longitudinal physiological
data to further elucidate the effects of trial interventions
upon host biology.4.2. Predicting and understanding treatment tolerance
in physiologically vulnerable populations
Treatment-related toxicity is a common and significant
concern related to anti-cancer therapeutics. In some in-
stances, treatment itself causes substantial physiological
perturbation, putting even “fit” individuals at increased risk
of morbidity and mortality (Deeg and Sandmaier, 2010;
Wood et al., 2013b). In other instances, a treatment may be
tolerated well by most, but physiologically “vulnerable” indi-
viduals are at increased risk of treatment-related harm. In
some cases, theremay bemore than one acceptable treatment
alternative, but with different levels of therapeutic intensity.
PGHD may provide information to help distinguish who is
most at risk for treatment-related toxicity.
lymphoma (Vitolo et al., 2014) and other diseases. Look-
ing to the future, it is likely that an entirely patient-
reported version of a CGA, complemented by novel
PGHD streams, could be developed for individuals of all
ages in order to predict andmeasure vulnerability before
and during treatment on cancer clinical trials.
Example: Chronic myeloid leukemia is a disease in which
adherence to a daily oral medication is critical to opti-
mize long term outcomes (Ibrahim et al., 2011). Potential
reasons for nonadherence range from medication side
effects, to psychosocial factors, to financial strain
(Dusetzina et al., 2014). PGHD has enabled the use of
smartphone-based technology that can track daily medi-
cation adherence (NCT01490983, 2014) as well as patient-
reported symptoms (Johnston et al., 2013). Similar strate-
gies could be used in cancer clinical trials, potentially
combinedwith other PGHD streams such as financial, so-
cial, or geolocation data, to understand reasons for treat-
ment nonadherence or discontinuation in other
contexts.
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A patient-reported symptom inventory was used to support
the approval of Jakafi (ruxolitinib), a kinase inhibitor used in
the management of myelofibrosis. PROs are frequently used
to support labeling claims of novel therapeutics. Regulatory
standards have been established regarding the design of PRO
endpoints intended to support label claims (FDA, 2009); the
key issues are reliability of the PRO measure, conceptual
equivalence between the PRO measure and the endpoint defi-
nition, and relevance of the endpoint to the study population.
These standards reflect methodological rigor that could guide
the development of other types of measurement based end-
points, such as those based on PGHD, particularly those
intended to reflect the patient’s experience, because they
require clear conceptual definition in addition to adequate
measurement reliability, in order for the data to be
interpretable.
Understanding the long-term effects of treatment on patients’
lives
In some clinical contexts, long-term health related quality
of life impairments are found in a significant minority of pa-
tients, despite “cure” of the underlying disease. The mecha-
nism for this finding is not always clear, and may in part
relate to symptom burden, among other contributors. PGHD
mayhelp to facilitate the longitudinalmeasurement of HRQOL
and functional status outside of clinic, and may identify fac-
tors associated with long term HRQOL or functional status
impairment.Example: Patient-reported symptom profiles can help
provide understanding about the nature and severity of
the proximal and distal symptom burden following
anti-cancer treatment. Recent work has demonstrated
the feasibility of frequent, longitudinal symptom profile
reporting even among very ill patient populations, such
as individuals undergoing autologous or allogeneic
stem cell transplantation (Wood et al., 2013a). Other
research has demonstrated the prevalence of high symp-
tom burden in stem cell transplant survivors who report
impaired HRQOL (Bevans et al., 2014). Given the preva-
lence of long-term HRQOL and functional status impair-
ment in a quantifiable percentage of stem cell transplant
recipients (Pidala et al., 2009), integrating longitudinal
symptom profiling (Wood et al., 2012) and other PGHD
streams such as sleep patterns (Jim et al., 2014), physical
activity, diet, and social support into clinical trials may
help to provide insight into why some individuals expe-
rience long term morbidity.4.4. Exploring reasons for treatment nonadherence or
discontinuation
Unfortunately, it is not always clear why some participants on
clinical trials are nonadherent to therapy or withdraw from
studiesdespite theabsenceofdiseaseprogressionordeath. Pre-
sumably, toxicity may play a role in this, but other reasons are
likely to contribute. PGHD has the potential to improve docu-
mentation of medication adherence, and to facilitate data
streams thatmay provide insight into reasons for study discon-
tinuation.AsPGHDtechnologyevolves, theremayevenbeways
to monitor therapeutic drug levels or metabolites from home.Predicting and understanding therapeutic outcomes
So far, we have discussed the integration of PGHD into can-
cer clinical trials as away to understand intermediate or ancil-
lary study endpoints. However, previous work has identified
the ability of patient-reported symptoms or HRQOL to predict
outcomes of patients on clinical trials. We believe that base-
line or early PGHD could be included in multivariate models
as a potential variable to predict progression or survival
following cancer treatment. Where baseline PGHD is informa-
tive regarding trial outcomes, it may have value as a stratifica-
tion factor for randomization.Example: In a recent studyof 11 different cancer sites from
30 European Organization for Research and Treatment of
Cancer (EORTC) randomized clinical trial data sets, inves-
tigators found that at least 1 HRQOL domain provided in-
dependent prognostic information (beyond clinical and
sociodemographic variables) for each cancer site
(Quinten et al., 2014). In another study, a symptom-
based lung score predicted overall survival and non-
relapse mortality in stem cell transplant recipients with
chronic graft versus host disease (Palmer et al., 2014).
Basedon theprognostic signal seen todate indiverse can-
cer settings from infrequently collected HRQOL and
symptom data, it is conceivable that PGHD streams of
frequent, longitudinal symptom, HRQOL, functional sta-
tus, and physical activity data may provide important
prognostic and perhaps predictive information at multi-
ple time points for patients on therapeutic clinical trials.
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clinical trials
In addition to the role of PGHD in an analytical or predictive
capacity, PGHD can also be used to facilitate supportive inter-
ventions on clinical trials. Some types of PGHD are amenable
to targeting through behavioral approaches, with subsequent
effects that can be measured with PGHD streams such as
physical activity, diet, and sleep patterns. Other types of
PGHD can be used to create alerts or to triage subsequent in-
terventions, such as notifying health care providers about
study participants who meet pre-specified patient-reported
symptom or vital sign thresholds. PGHD could also be used
to monitor adherence and to alert or remind participants
about taking study drugs or following protocol procedures.Example: In some instances, differentPGHDstreamscanbe
brought together to develop and track the effects of inter-
ventions upon both PGHD and clinical endpoints. For
example, a home-based, unsupervised exercise interven-
tion could be developed to improve the ability of partici-
pants to tolerate anti-cancer therapies, with a goal of
improving long-term functional status and health-
related quality of life. PGHD (examples in parentheses)
could be used to track adherence to the exercise interven-
tion (accelerometry), the ability of participants to achieve
target heart rates (vital signs), the effects of the interven-
tion upon short term physiology (post-exercise vital signs,
sleep patterns, patient-reported symptoms), and the ef-
fects of the intervention upon long term patient-centered
outcomes (patient-reported functional status, health-
related quality of life). In a randomized fashion, those
receiving the intervention could be compared to controls
in order to determine the effect of the intervention upon
the achievement of intermediate and long-term clinical
outcomes, with the breadth of collected PGHD used to
analyze and interpret the results. A social component
could be integrated into this design so that participants
couldmonitor and support one another, and to the extent
that these PGHDdata are collected in a decentralizedway,
virtual web-based recruitment and enrollment strategies
could be considered. These features might be attractive
to technology-savvy individualswhoare traditionallydiffi-
cult to enroll onto clinical trials, such as adolescents and
young adults (Wood and Lee, 2011).5. Agenda for future methodological research
Though there aremany potential applications of PGHD to clin-
ical research, we are in a very early stage of learning how to
obtain and use these data effectively. Here, we summarize
several of the issues that we think will be critical to address
from a methodological standpoint moving forward:5.1. Feasibility
Several PGHD streams are owned by companies with proprie-
tary interests in the devices used to generate the data and thealgorithms behind the data generation. What are the costs
associated with acquiring sufficient devices per patient to
generate the required data streams for a given study?What is-
sues are involved in accessing and uploading raw data from
different vendors? How much complexity is required to map
and combine different PGHD streams into an analyzable
dataset?
From a patient standpoint, will patients reliably wear de-
vices that require proximity to the patient to generate data?
Will patients reliably input data for PGHD streams that require
patient data entry? Are there population subgroups who are
uncomfortable with these types of data collection, and can
these concerns be addressed? How will data missingness be
handled? As new technologies are developed (e.g. replaceable
skin adhesive patches to replace wristbands or belt clips), as
PGHD streams take different forms, and as these technologies
are applied to different patient populations, these exercises
will need to be repeated.
5.2. Data reliability
Many PGHD streams have been developed as consumer de-
vices rather than as research-grade data sources. For example,
whether a FitBit, Jawbone Up, Nike þ FuelBand, or Actigraph
GT3x þ all measure activity and/or sleep in the same way,
and whether the results from these devices are interchange-
able, is unclear. Other emerging PGHD streams are also rela-
tively untested in comparison to gold standard assessments,
such as popular dietary/nutrition trackers in relationship to
calorimetry. Outside the context of academic research, there
have not been strong incentives to perform validation studies
of these data sources, but such studies will be required in or-
der to understand data quality. Clinical trialists will need to
decide what level of measurement reliability between these
devices and their ‘gold standard’, if one exists, is acceptable
for each research study, as there may be tradeoffs to consider
between feasibility, cost, and data quality.
5.3. Matching PGHD sources to therapeutic indications
We do not yet knowwhich PGHD sources will be best suited to
which research context. For example, which PGHD are most
relevant to men with advanced prostate cancer e perhaps
pedometry/accelerometry and patient-reported symptoms
including fatigue and pain? What is the potential role of sleep
tracking in the adjuvant vs metastatic cancer setting, and in
younger vs older adults? Are dietary PGHD obtained pre-
operatively useful in predicting outcomes after cancer sur-
gery? If a comprehensive PGHD functional assessment can
be developed that is analogous to the comprehensive geriatric
assessment, in which settings (e.g. stem cell transplantation?)
is this most likely to be useful? It is likely that a number of
exploratory studies using multiple PGHD streams will need
to be conducted in multiple cancer settings in order to deter-
mine which data outputs aremost relevant to which contexts.
In addition to statistical analysis, qualitative methods such as
interviews with patients and other stakeholders is extremely
productive in identifying relevant domains and in providing
context for the interpretation of data (e.g. what does “total
daily steps” indicate for patients with advanced cancer).
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Some devices that provide PGHD qualify as medical devices
(e.g. blood glucose monitors) and are subject to FDA review.
Regulatory approval for a new medical device is sought by
the manufacturer. However, the use of a device that substan-
tially deviates from the intended or approved use may require
additional review. In addition, clinical trial protocols including
PGHD may raise new questions about risk and benefits to pa-
tients be considered during IRB review. As we design clinical
research protocols with more complex collection of PGHD
(e.g. multiple streams of data or devices that require the up-
load data to a web account), or new types of devices, we are
paying particular attention to issues of data security and pri-
vacy, and other potential risks to the patient.
5.5. Using PGHD to model relevant outcomes
Perhaps most importantly, considerable effort will need to be
devoted to making meaning out of large amounts of PGHD.
Many PGHD streams produce continuous data across long pe-
riods of time. How these data streams interact with one
another, and how they anchor against clinically relevant end-
points, will need to be investigated. For example, when we
currently conceptualize “performance status” in clinical
oncology, we think about two commonly used scales (Kar-
nofksy Performance Status (KPS) and Eastern Cooperative
Oncology Group Performance Status (ECOG PS)) which are
scored from 0 to 100 or 0e4 and which are used by clinicians
to assess patient level of day to day functioning. Though the
accuracy and discriminatory capacity of these scales are
limited, they are used to make important cancer-related deci-
sions (e.g. prescription of chemotherapy) and to evaluate the
effects of cancer or cancer treatment upon patient outcomes.
Can we conceptualize a new methodology for patient-
reported performance status in clinical oncology? An obvious
possibility, simply adapting one of the existing scales to a
patient-reported version, such as the patient-reported ECOG
PS, has been attempted with some success (Basch et al.,
2005). Current sources of PGHD now offer the ability to do
something similar using a richer series of data sets with the
promise of more clinically meaningful outcomes. However,
much work will need to be done in order to understand which
data sets to combine and how this should be done. For
example, pedometry/accelerometry, patient-reported func-
tional status, and patient-reported symptoms are potential
candidates for such a composite measure, but we will need
to learn how these data should be represented and combined,
over what period of time, and whether these are the right
PGHD streams, in order to draw conclusions about the clinical
utility of a patient-generated performance status index in
comparison to existing measures. Other studies will need to
be conducted to understand the association of PGHD with
additional clinical endpoints. For example, given the expected
cytokine dysregulation with T-cell immunotherapy (Maude
et al., 2014), is there a combination of patient-reported symp-
toms, sleep patterns, activity levels, and blood pressures that
is associated with early treatment effects or tumor responses
to this treatment modality? Do certain constellations of PGHD
predict long-term clinical outcomes in these scenarios? Inthese analyses, how should these data be handled e as abso-
lute values or as changes from baseline? How should data be
compared to expected values in similar patient populations?
A variety of modeling exercises will need to be conducted to
begin to address these questions.6. Concluding thoughts
The current environment represents an interesting and
exciting opportunity for the incorporation of these new forms
of PGHD into cancer clinical trials. With recent announce-
ments by major consumer technology companies, and
increasing interest in PGHD throughout academic institutions
and government entities, there is an unprecedented conver-
gence of resources and interest in this area. However, we are
living in the earliest days of this new era e though we have
identified several possible opportunities in this review,
much work needs to be done to identify, acquire, validate,
combine, and model relevant PGHD streams so that these
data can be useful in the research context and ultimately in
clinical care.
What does the long-term future of PGHD look like? In the
current big data era, we are increasingly recognizing that
new computational strategies and systems biological ap-
proaches will be necessary to mine and make sense of the
genomic, proteomic, and phenotypic data that we are now
generating in clinical care and research. PGHD represents
an important new form of data to be added to this new way
of looking at health and disease. From a broader perspective,
a new paradigm is emerging: each individual has the ability
to generate an analyzable “personal data cloud of billions
of data points” that will ultimately help to catalog the transi-
tions between, and predictors of, health and disease (Hood
and Price, 2014; Chen et al., 2012). Though these data can
be aggregated to drive population insights, the amount and
complexity of data allows each person to serve as his or
her own control over time, creating a series of “n of 1”
studies.
The emergence of PGHD offers an exciting opportunity to
catalyze the application of “big data” to the context of clinical
cancer research. In the future, leveraging the power of multi-
ple continuous, personalized data streams will allow us, as a
research and clinical community, to derive maximal insight
from the participation of each patient in each trial. Such an
approach, we believe, will optimize trial efficiency, generate
biological and clinical insights into cancer behavior and treat-
ment response, and, in the end, respect the profound commit-
ment that every participant in a clinical trial makes to the
advancement of cancer research.R E F E R E N C E S
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